Founded in 1994, the Medical City Dallas Blood and Marrow Transplant Program has remained accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) and the National Marrow Donor Program (NMDP). Under the guidance of the medical director, Dr. Vikas Bhushan, every type of transplant is performed at Medical City Dallas, including both adult and pediatric autologous, allogeneic, related, unrelated, umbilical cord, CAR-T, and haploidentical. The haploidentical transplant has garnered interest over recent years, of which 40 were performed in 2021. Additionally, the Cellular Therapy Laboratory, where the stem cells are processed and stored, is FDA-registered and led by Dr. Joel Weinthal, the medical director of the Cellular Therapy Lab and Apheresis. Amidst the growth, the program has adopted several processes and projects that have become best practices and unique opportunities to enhance patient care and team communication. To name a few are the following: new transplant housing arrangements, the Patient and Caregiver Empowerment Program (PACE), weekly COVID-19 task force, PASSPORT for patient ease and access through transplant milestones, and the deployment of ONCAlert and the Cellular Therapy Alert Program (CTAP) to efficiently triage oncology patients when arriving to the ER.